Skip to main content

Xultophy FDA Approval History

FDA Approved: Yes (First approved November 21, 2016)
Brand name: Xultophy
Generic name: insulin degludec and liraglutide
Dosage form: Injection
Previous Name: IDegLira
Company: Novo Nordisk
Treatment for: Diabetes, Type 2

Xultophy 100/3.6 (insulin degludec and liraglutide) is a fixed-ratio combination of the long-acting basal insulin analog, insulin degludec (Tresiba), and the a glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Development timeline for Xultophy

DateArticle
Nov 21, 2016Approval Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes
Sep  2, 2016FDA Extends Regulatory Review Period for IDegLira by Three Months
May 24, 2016IDegLira Receives Positive 16-0 Vote in Favour of Approval from FDA Advisory Committee

See also

Xultophy (insulin degludec and liraglutide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer